ES2269206T3 - Ligandos de neurofilina para tratar trastornos oculares. - Google Patents

Ligandos de neurofilina para tratar trastornos oculares. Download PDF

Info

Publication number
ES2269206T3
ES2269206T3 ES00980231T ES00980231T ES2269206T3 ES 2269206 T3 ES2269206 T3 ES 2269206T3 ES 00980231 T ES00980231 T ES 00980231T ES 00980231 T ES00980231 T ES 00980231T ES 2269206 T3 ES2269206 T3 ES 2269206T3
Authority
ES
Spain
Prior art keywords
piperidinocarboxylate
oxopentanoyl
propenyl
dimethyl
phenylacetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00980231T
Other languages
English (en)
Inventor
Iok-Hou Pang
Mark A. Hellberg
Abdelmoula Namil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ES2269206T3 publication Critical patent/ES2269206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

El uso de un ligando de neurofilina que no muestra actividad inmunosupresora, para la fabricación de un medicamento para el tratamiento de un mamífero que padece de glaucoma, donde el ligando de neurofilina es un derivado de ácido pipecólico que es 1-(3, 3- dimetil-2-oxopentanoil)-2-piperidinocarboxilato de (E)- 3-(3, 4-diclorofenil}-2-propenilo; 1-(3, 3-dimetil-2- oxopentanoil)-2-piperidinocarboxilato de (E)-3-(3, 4, 5- trimetoxifenil)-2-propenilo; 1-(3, 3-dimetil-2- oxopentanoil)-2-piperidinocarboxilato de (E)-3-fenil-2- propenilo; 1-(3, 3-dimetil-2-oxopentanoil)-2- piperidinocarboxilato de (E)-3-((3-(2, 5-dimetoxi)- fenilpropil)fenil)-2-propenilo; 1-(3, 3-dimetil-2- oxopentanoil)-2-piperidinocarboxilato de (E)-3-(1, 3- benzodioxol-5-il)-2-propenilo; 1-(2-oxo-2-fenilacetil)- 2-piperidinocarboxilato de 4-(4-metoxifenil)butilo; 1- (2-oxo-2-fenilacetil)-2-piperidinocarboxilato de 3- fenilpropilo; 1-(2-oxo-2-fenilacetil)-2- piperidinocarboxilato de 3-(3-piridil)propilo.
ES00980231T 1999-11-12 2000-10-24 Ligandos de neurofilina para tratar trastornos oculares. Expired - Lifetime ES2269206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16513799P 1999-11-12 1999-11-12
US165137P 1999-11-12

Publications (1)

Publication Number Publication Date
ES2269206T3 true ES2269206T3 (es) 2007-04-01

Family

ID=22597584

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00980231T Expired - Lifetime ES2269206T3 (es) 1999-11-12 2000-10-24 Ligandos de neurofilina para tratar trastornos oculares.

Country Status (16)

Country Link
US (1) US20060083774A1 (es)
EP (1) EP1227859B1 (es)
JP (1) JP2003514015A (es)
AR (1) AR034103A1 (es)
AT (1) ATE335524T1 (es)
AU (1) AU784347B2 (es)
BR (1) BR0015486A (es)
CA (1) CA2386579A1 (es)
CY (1) CY1106232T1 (es)
DE (1) DE60029985T2 (es)
DK (1) DK1227859T3 (es)
ES (1) ES2269206T3 (es)
HK (1) HK1046108B (es)
PT (1) PT1227859E (es)
TW (1) TW200511984A (es)
WO (1) WO2001035948A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178977A1 (en) * 2020-03-06 2021-09-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating ocular disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
DE69907418T2 (de) * 1998-02-23 2003-11-13 Fujisawa Pharmaceutical Co Verwendung von makroliden zur behandlung von glaukom
US6399648B1 (en) * 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
JP4503180B2 (ja) * 1998-08-14 2010-07-14 ジーピーアイ ニル ホールディングス インコーポレイテッド 視覚および記憶障害のための組成物および使用法

Also Published As

Publication number Publication date
TW200511984A (en) 2005-04-01
PT1227859E (pt) 2006-12-29
WO2001035948A3 (en) 2002-01-17
AU784347B2 (en) 2006-03-16
ATE335524T1 (de) 2006-09-15
AR034103A1 (es) 2004-02-04
DE60029985D1 (de) 2006-09-21
EP1227859A2 (en) 2002-08-07
AU1752201A (en) 2001-05-30
DK1227859T3 (da) 2006-12-11
JP2003514015A (ja) 2003-04-15
US20060083774A1 (en) 2006-04-20
WO2001035948A2 (en) 2001-05-25
EP1227859B1 (en) 2006-08-09
CA2386579A1 (en) 2001-05-25
BR0015486A (pt) 2002-07-02
HK1046108A1 (en) 2002-12-27
CY1106232T1 (el) 2011-06-08
DE60029985T2 (de) 2007-02-01
HK1046108B (zh) 2007-01-05

Similar Documents

Publication Publication Date Title
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
Plummer et al. Comparison of the effects of topical administration of a fixed combination of dorzolamide–timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs
US7105504B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
KR20100050502A (ko) 도파민계가 붕괴되어 있는 장애 또는 병태의 증상을 감소 또는 치료하기 위한 ｋｃｎｑ 포타슘 채널 개방제의 용도
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
WO2007130429A3 (en) Histone deacetylase and tubulin deacetylase inhibitors
EA200400943A1 (ru) Тиазольные и оксазольные производные, которые модулируют ppar активность
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
TW200803839A (en) Use of a CB1 antagonist for treating side effects and negative symptoms of schizophrenia
MX2013005705A (es) Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
ATE398449T1 (de) Verwendung von azetidincarboxamidderivaten in therapie
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
RU2003131970A (ru) Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ES2269206T3 (es) Ligandos de neurofilina para tratar trastornos oculares.
SE0002729D0 (sv) Novel compound form
EA200400302A1 (ru) Способ лечения первичной бессонницы